ABVC BioPharma, Inc. Share Price
NASDAQ: ABVC | Micro CapABVC BioPharma, Inc. Stock Performance
Open $1.02 | Prev. Close $1.00 | Circuit Range N/A |
Day Range $1.02 - $1.02 | Year Range $0.90 - $3.38 | Volume 400 |
Average Traded $1.02 |
ABVC BioPharma, Inc. Share Price Today
As of 10 August 2026, ABVC BioPharma, Inc.'s share price is $1.02. The stock opened at $1.02, compared to its previous close of $1.00. During today's trading session, ABVC BioPharma, Inc.'s share price traded between $1.02 and $1.02, with an average price of $1.02. Over the past 52 weeks, the stock has recorded a high of $3.38 and a low of $0.90. In terms of performance, ABVC BioPharma, Inc.'s share price has declined by 20.23% over the last six months and is down 63.26% on a year-on-year basis.
ABVC BioPharma, Inc. Share Price Chart
ABVC BioPharma, Inc. Stock Fundamentals & Key Indicators
Market Cap $20.61M | PE Ratio (TTM) -2.63 | Dividend Yield N/A |
EPS (TTM) $-0.39 | Revenue (TTM) $509589.00 | Return On Equity (TTM) -75.39% |
Profit Margin -1643.87% | Debt to Equity 0.55 | Quarterly Earnings Growth YoY -994.80% |
ABVC BioPharma, Inc. Quarterly Profit & Loss
All figures in USD
ABVC BioPharma, Inc. Annual Profit & Loss
All figures in USD
About ABVC BioPharma, Inc.
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is headquartered in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
ABVC BioPharma, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $1.02 | $1.02 | +1.08% |
Jul 2026 | $1.54 | $1.01 | -35.82% |
Jun 2026 | $1.29 | $1.58 | +12.86% |
May 2026 | $1.02 | $1.40 | +30.23% |
Apr 2026 | $0.97 | $1.07 | +10.94% |
Mar 2026 | $1.38 | $0.97 | -24.59% |
Feb 2026 | $2.00 | $1.28 | -36.67% |
Jan 2026 | $2.11 | $2.03 | -4.29% |
Dec 2025 | $2.62 | $2.12 | -21.19% |
Nov 2025 | $2.80 | $2.69 | -2.89% |
Oct 2025 | $3.00 | $2.77 | -10.06% |
Sep 2025 | $2.83 | $3.08 | +10.39% |
ABVC Share Price FAQs
What is ABVC BioPharma, Inc. share price today?
What is the 52 week high and 52 week low of ABVC BioPharma, Inc. stock?
What is ABVC's market capitalisation today?
What is ABVC's net income for the last quarter?
What is the 5 year returns of ABVC?
What is the high & low stock price of ABVC today?
Can I buy ABVC shares in India?